Kornimate/medical-research-clean huggingface dataset:
the relationship between oxytocin level and postpartum depression

Conditions: Oxytocin Deficiency; Postpartum Depression; Prenatal Stress

Summary: there are studies in the literature that associate oxytocin level with postpartum depression. this study was carried out to investigate the relationship between oxytocin levels measured during pregnancy and postpartum depression symptoms.

introduction and purpose: there are studies in the literature that associate oxytocin level with postpartum depression. this study was carried out to investigate the relationship between oxytocin levels measured during pregnancy and postpartum depression symptoms. method: the study was conducted with 70 women who met the research criteria. data collection was done in two interviews. the first meeting is 30-38 at the week of gestation, the second interview is 4-12 at the week of postpartum. it was done between weeks. in each interview, a data collection form was applied first and then a saliva sample was taken. data collection form; the questions prepared by the researchers consisted of the edinburgh postnatal depression scale (epds) and beck depression inventory (bdi). the data were analyzed using spss 22.0 program and the significance value was taken as p \<0.05.

Eligibility criteria:
inclusion criteria: * 18 years of age or older, and having a pregnancy of 30 weeks or more exclusion criteria: * previous mental illness history, miscarriage or stillbirth history, multiple pregnancy, fetal malformation, antidepressant or anxiolytic drug use, existing chronic disease,preterm labor is the development of maternal or neonatal complications at birth, hospitalization in the neonatal intensive care unit or congenital disease.

Keywords: oxytocin postpartum depression oxytocin and depression
pylarify® pet/ct or pet/mri in men with favorable intermediate risk (fir) prostate cancer

Conditions: Prostate Cancer

Summary: the purpose of this study is to learn whether pylarify pet imaging (study scan) can safely and accurately detect the presence or absence of prostate cancer growing beyond the prostate gland in men with favorable intermediate risk prostate cancer. participants will receive a single dose of pylarify injection followed by a single whole-body pet/ct or pet/mri scan acquired at 1 to 2 hours after pylarify injection. participants with positive study scan results that are suspicious for prostate cancer outside of the prostate gland may be asked to undergo additional diagnostic test(s) and/or recommend certain treatment(s) for prostate cancer within 2 to 90 days after the study scan. participants will be monitored for up to 12 months to collecting information about treatment they receive for prostate cancer and results of regular psa blood draws if ordered by doctors for up to 12 months after the study scan.


Eligibility criteria:
inclusion criteria: 1. patients must have the ability to understand and sign an approved informed consent form (icf) 2. patients must have the ability to understand and comply with all protocol requirements 3. patients must be ≥ 18 years of age 4. patients must have an eastern cooperative oncology group (ecog) performance status of 0 to 2 5. patients with life expectancy of at least 13 months as determined by the investigator 6. patients must have confirmed favorable intermediate risk (fir) adenocarcinoma of the prostate per 2023 nccn guidelines. fir risk group confirmation includes all the following: * 1 intermediate risk factor (ct2b-ct2c or isup grade group 2 or psa 10-20 ng/ml) * isup grade group 1 or 2 * \<50% biopsy cores positive (e.g., \<6 of 12 cores) note: date of the prostate biopsy should be no sooner that 2 weeks and no later than 3 months prior to pylarify pet imaging exclusion criteria: 1. patients administered any high energy (\>300 kev) gamma-emitting radioisotope within 5 physical half-lives prior to day 1 (pylarify imaging) 2. previous prostate cancer treatment including radiation, androgen deprivation therapy, brachytherapy, surgery, prostate ablation, hormonal therapies or investigational therapy 3. known hypersensitivity to the components of pylarify or its analogs 4. patients with any medical condition or other circumstances that, in the opinion of the investigator, compromise the safety or compliance of the subject to produce reliable data or complete the study 5. patients who have any radiographic evidence of t3, n1 or m1 disease on soc imaging (if performed)

Keywords: prostate cancer favorable intermediate risk pylarify pet
comparative effects of blow bottle and acapella along with diaphragmatic breathing in patients with pneumonia

Conditions: Pneumonia

Summary: pneumonia is the inflammation of lung parenchyma involving lungs alveoli and is a leading cause of lower respiratory tract infections and deaths around the globe and the number rises greatly after the covid-19 pandemic. the symptoms of pneumonia is cough, fever, dyspnea, myalgia, altered blood gas ratio, and mental alteration. treatment and management of this disease varies from patient to patient according to its severity stages .blow bottle supports the patient to remove excess secretions to increase pressure in the airways. this opens up the passageways in bronchioles, air behind the mucus push it into the larger airways .it will be easy to remove mucus by coughing or huffing. hypoximia is a clinical feature of pneumonia that requires a fraction of inspired oxygen fio2 of 0.50 to maintain an oxygen saturation of 92%. this research of randomized clinical trial will check the comparative effects of blow bottle technique and acapella along with diaphragmatic breathing in patients with pneumonia by taking sample of 50 patients through non probability convenience sampling and randomly allocating them to two groups a and b out of which a will receive both blow bottle and diaphragmatic breathing training, b will receive acapella with diaphragmatic breathing upto the duration of 3 days per week for upto 4 weeks. pre and post training outcomes of pulmonary function will be measured through bcss ,oxygen saturation through pulse oximeter, and disease severity through pneumonia severity index, and who qol questionnaire. the data will be analyzed through spss 21


Eligibility criteria:
inclusion criteria: * patients in the acute pneumonia * age40-60 years. * both male and female * patients with unstable health conditions * participants were willing to participate exclusion criteria: * patients with physical or cognitive limitations. * patients with a history of chronic respiratory conditions such as copd, bronchitis, or asthma * pregnant or breastfeeding women. individuals with musculoskeletal or neurological conditions * patients with contraindications to chest percussion therapy, such as recent surgery or trauma to the chest area. * patients with severe pneumonia requiring immediate care

Keywords: blow bottle acapella diaphragmatic breathing pneumonia
nutritional status among upper gastrointestinal cancer patients upon admission

Conditions: Upper Gastrointestinal Cancer Patients Upon Admission; Nutritional Status

Summary: cross-sectional study. data on clinical, anthropometric, biochemical profile and dietary intake upper gastrointestinal cancer patients upon admission are traced and collected.

as per routine care, on the day of admission, nutrition assessment and clinical examination of all in-patients will be carried out. patient screening will be done by assigned investigator based on the dietitian censes based on inclusion and exclusion criteria. the investigator will trace the data from medical system and record in the data collection form.

Eligibility criteria:
inclusion criteria: * admitted ugic patient * seen by dietitian in ward exclusion criteria: * not admitted in ward * aged \<18 years old * non-malaysian

Keywords: upper gastrointestinal cancer patients upon admission nutritional status
evaluation of janus kinase_3 in juvenile onset systemic lupus erythematosus

Conditions: Systemic Lupus Erythematosus

Summary: one of the best understood mechanisms by which cytokines activate signals, thus eliciting specific responses in target cells, involves enzymes such as janus kinases (jaks) and transcriptional factors such as signal transducers and activators of transcription (stats). for immune mediated diseases, both activating and inactivating mutations of jaks and stats may cause abnormalities in immune homeostasis. polymorphisms of jak/stat genes have been linked to susceptibility for rheumatoid arthritis (ra) , systemic lupus erythematosus (sle), psoriatic arthritis (pa) and inflammatory bowel disease (ibd) . janus_kinase 3 expression will be evaluated in the serum and renal tissue of lupus patients during active stage of the disease through this study

investigators will assess the relationship between the expression of janus_kinase 3 and the clinical and laboratory parameters of disease activity . disease activity will be assessed through the systemic lupus erythematosus disease activity index (sledai). also, investigators will evaluate the relationship between janus_ kinase 3 expression and histopathological classes of lupus nephritis according to the 2003 international society of nephrology/ renal pathology society (isn/rps) classification of lupus nephritis. this will be done through janus_kinase 3 assessment in the blood and renal tissue of lupus patients.

Eligibility criteria:
inclusion criteria: * age younger than 16 years. * active disease stage * patients with biopsy proven lupus nephritis according to isn/rps classification criteria of lupus nephritis exclusion criteria: * lupus patients in remission. * lupus patients with end stage renal disease. * lupus patients with secondary thrombotic thrombocytopenic purpura (ttp) and hemolytic uremic syndrome (hus). * patients with moderate or severe infection

Keywords: janus-kinase3 active lupus
study to compare suture material in closure of uterine incision in cesarian section

Conditions: Hysterotomy Closure

Summary: prospective single blinded trial comparing standard synthetic suture material to a synthetic barbed suture in closure of uterine incision, during cesarean section procedures.

cesarean section is one of the most common medical procedures women of child bearing age undergo, in the united states and the world. this trial is designed to provide information and possible recommendation as to suture material used during closure of the uterus during that procedure. our intent is to provide data relating to time of uterine closure, blood loss, and post operative pain. these conclusions may provide substantiated recommendations as to self locking and tying suture material in the performance of cesarean section as related to readily available synthetic suture material, which has the need for standard suture knot placement.

Eligibility criteria:
inclusion criteria: * women of childbearing age undergoing primary or repeat cesarean section using regional anesthesia. exclusion criteria: * general anesthesia * non-consent to participation
measles vaccine: is there a protective role in covid 19 pandemic?

Conditions: Coronavirus (COVID-19)

Summary: the following two mechanisms that explain the ability of measles vaccine to cause partial protection against covid-19. the first is that measles vaccine may increase the ability of the immune system to fight off pathogens other than measles due to the generated bystander immunity that would enhance the overall immunity against the new coronavirus. the second is that sars-cov-2 is proven to have structure similarities with measles, which may cause cross-reactivity and immunity between measles vaccines and covid-19, leading to partial protection against covid-19 in vaccinated subjects

objectives: 1. to identify measles igg titre in sars-cov2 infected patients . 2. correlate level of measles igg titre with the clinical severity of covid-19 disease. secondary objective to find an association of the postulated protective role of measles vaccine and sars-cov2 infection criteria: inclusion criteria:included patients would be divided into 3 groups according to clinical severity of covid-19 disease (mild ,moderate \& severe) * all patients with confirmed covid 19 confirmed by positive pcr . . * any age or gender. exclusion criteria: - any patient refusing to be involved in the study. methods: * informed consent will be taken from each subject * full clinical examination. * evaluation of measles antibody titer: the measles virus igg antibody titer will be determined quantitatively by elisa for quantitative determination of igg class antibodies against measles virus in human serum or plasma (citrate, heparin). - anonymous data will be retrieved from the admitted patients' files, such as: * cbc, crp, ast, alt, esr, serum ferritin \& sars cov 2 rna pcr swab results. * chest x ray and/or ct chest.

Eligibility criteria:
inclusion criteria: * all patients with confirmed covid 19. * any age or gender exclusion criteria: * - any patient refusing to be involved in the study
evaluation of glycemic changes during exercise in children with type 1 diabetes

Conditions: Type 1 Diabetes

Summary: the objectives of the study are: 1) to evaluate the effects of moderate exercise on sg evolution without insulin dose modification in patients with t1d under continuous subcutaneous insulin infusion (csii) and multiple daily injection (mdi) therapy, and compare differences between these 2 groups; 2) to evaluate the impact of insulin dose modification (bolus, basal, reduction or increase, based on sg evolution profile obtained after first exercise) before and/or during moderate exercise on t1d children under csii and mdi regimen, and compare differences between these 2 groups.

intervention and procedures: a) the patients will first be assigned to standardized moderate-to-vigorous exercise for sg determination; b) similar exercise will then be repeated with preemptive adaptation of insulin dose (tailored on sg evolution during first exercise) for determination of potential influences on sg evolution. intervention plan: * at first visit (day \[\>18h\] before exercise): setting of a continuous glucose monitoring system * at second visit: moderate-to-vigorous exercise with treadmill. * at third visit (2 days after exercise): removal of cgms * at fourth visit (day \[\>18h\] before fifth visit): setting of a continuous glucose monitoring system * at fifth visit: moderate exercise with treadmill, and insulin dose modification (basal rate, bolus, reduction, increase) * at sixth visit (2 days after exercise): removal of cgms * total number of visits: 6 * the exercises will be performed between 1 and 2 hours after breakfast or after lunch; the second exercise will be performed ≥2 weeks after the first exercise. controls: * moderate exercise with and without modification of insulin dose in mdi patients (by comparison with csii patients). mdi patients will be matched to csii patients according to gender, age, bmi (±0.5 z-score) and hba1c levels (±1%) to exclude any bias in patient allocation. * moderate exercise without modification of insulin dose at first visit (by comparison with modification of insulin dose).

Eligibility criteria:
inclusion criteria: * diagnosis of t1d (according to the ispad 2011 guidelines) * t1d outside of partial remission phase (defined according to the idaa1c definition \[diabetes care 2007\], being equal to a1c (%) + \[4 x insulin dose (units per kilogram per 24 h)\] and at least \> 2 years after t1d diagnosis (defined as the first day of insulin therapy) exclusion criteria: * non-type 1 diabetes * severe neonatal asphyxia (defined as apgar score 3 or less after 5 min), children born small for gestational age, chronic systemic disease, active malignancy, hypothyroidism, hypopituitarism, developmental delay, bladder dysfunction, obesity, carnitine deficiency, β-oxidation defect, cardiac malformations, dysrhythmia * intake of drugs interfering with insulin sensitivity (e.g. corticosteroids, gh). * hba1c \>9.5% at the time of enrollment in the study.
clinician-supported ptsd coach vs. self-managed ptsd coach

Conditions: PTSD

Summary: ptsd coach is a mobile application (app) that aims to teach individuals self-management strategies for symptoms of post-traumatic stress disorder (ptsd). despite ptsd coach's use of evidence-based cognitive behavioral strategies there is still a need to test the effectiveness of the app in managing ptsd symptoms. there is research evidence that self-management programs are often underutilized, but that clinician contact can increase patient involvement. the addition of clinician support may enhance the utilization and effectiveness of the ptsd coach. in phase 1 the investigators propose to conduct stakeholder interviews with primary care (pc) and mental health (mh) leadership staff to investigate barriers and facilitators to implementing clinician-supported (cs-ptsd coach) to increase the uptake, use, and impact of ptsd coach by pc patients. the interviews will inform the development of a cs-ptsd coach protocol and manual that will be used in phase 2. in phase 2 the investigators propose to conduct a feasibility study where 30 (20 eligible) pc veterans with diagnostic-level or subthreshold ptsd symptoms will be randomized to receive self-managed (sm) ptsd coach or cs-ptsd coach. the investigators' specific aims are to 1) investigate the feasibility of recruiting and retaining participants and delivering the sm and cs conditions and 2) conduct a preliminary investigation of the efficacy of sm vs. cs. the investigators predict that cs will lead to greater treatment gains than sm. effect sizes will be generated for the following outcomes: a) reductions in ptsd, depression, and general distress, and increases in health-related functioning, b) increases in knowledge about ptsd symptoms, ptsd management strategies, and patient coping self-efficacy, c) increases in initiation of tradition ptsd treatments.


Eligibility criteria:
inclusion criteria: 1. enrolled in primary care at the syracuse vamc, 2. significant ptsd symptoms. total ptsd checklist score ≥ 40. exclusion criteria: 1. gross cognitive impairment (as measured by the blessed orientation-memory-concentration; bomc) 2. suicide attempt or intent to commit suicide in the last two months (as measured by the columbia- suicide severity rating scale 3. psychotherapy or mental health counseling for ptsd in the last two months that was received outside of va primary care 4. a new psychotropic medication or a change in dose of a psychotropic medication for ptsd in the last two months that was received outside of va primary care 5. intent to begin ptsd treatment in specialty care
application of artificial intelligence in precision medicine and healthcare

Conditions: Myasthenia Gravis

Summary: this study aims to propose an intelligent health robot that utilizes remote intelligent robots to assist patients with disease-related issues, enabling them to address their problems promptly.

utilizing an information architecture system, a voice-based artificial intelligence program will be developed. the symptoms of major diseases and related knowledge will be input into this system to construct a dedicated disease platform. this platform will allow patients to remotely access it, enabling them to promptly understand and address disease-related issues, thereby improving convenience for patients.

Eligibility criteria:
inclusion criteria: 1. patients diagnosed with myasthenia gravis by a physician. 2. age 20 years and above. 3. able to use a smartphone. exclusion criteria: 1. individuals not diagnosed with myasthenia gravis. 2. individuals who do not use smartphones or tablets. 3. individuals who withdraw from the group midway. 4. individuals unwilling to participate in interviews.

Keywords: myasthenia gravis ai
a phase ll study of neoadjuvant short-course radiotherapy followed by ivonescimab and chemotherapy in pmmr/mss locally advanced rectal cancer

Conditions: Rectal Adenocarcinoma

Summary: the purpose of this study is to evaluate the efficacy and safety of short-course radiotherapy followed by ivonescimab and chemotherapy in participants with pmmr/mss locally advanced rectal cancer. patients were randomly assigned to experimental group a or control group b according to a 1:1 ratio. in group a, patients will receive neoadjuvant short-course radiotherapy followed by ivonescimab and chemotherapy. in group b, patients will receive neoadjuvant short-course radiotherapy followed by chemotherapy. after neoadjuvant treatment, the patients and investigator could choose one of the following treatments:(1) surgery. the patients will receive surgery within 4-8 weeks after the last dose of capecitabine, and the surgical method is selected by the investigator, (2) watch and wait (only for patients with clinical complete response after neoadjuvant therapy).


Eligibility criteria:
inclusion criteria: 1. age between 18 and 75 years; 2. ecog perfommance status of 0 or 1; 3. life expectancy: more than 2 years; 4. histologically proven rectal adenocarcinoma; 5. tumor biopsy immunohistochemistry proven pmmr, positive for four proteins, mlh1, msh2, msh6 and pms2, or mss determined by gene testing; 6. according to the 8th edition of the ajcc staging manual, clinical stage ct3-4nanym0 or ctxn+m0 of ii-iii rectal cancer was determined by magnetic resonance imaging (mri)±transrectal ultrasonography/ ultrasound endoscopy. lower edge of the tumor was ≤ 12 cm from the anal verge; 7. eligible for r0 surgery; 8. no prior anti-tumor treatment for rectal cancer,including radiotherapy,chemotherapy, immunotherapy, biologics, small molecule targeted therapy, etc; 9. adequate organ function; 10. males or females with reproductive ability who are willing to use contraception in the trial; exclusion criteria: 1. any distant metastasis or inoperable disease, regardless clinical stage; 2. previous (within 5 years) or concurrent other malignant tumors, excluding those that have been cured; 3. current presence of gastric intestine obstruction, bleeding or perforation which need emergency surgery; 4. multiple primary rectal cancers; 5. previous pelvic or abdominal radiotherapy; 6. difficulty swallowing; 7. current presence of uncontrolled combined disease; 8. active clinical infections; 9. history of severe bleeding tendency or coagulation dysfunction; 10. presence or history of immunodeficiency; positive for hiv antibodies, current long-term use of systemic corticosteroids or other immunosuppressants; 11. subjects with known active tuberculosis (tb); suspected active tb should be excluded by clinical examination, known active syphilis infection; 12. received a live vaccine within 30 days prior to the study, or plan to receive a live vaccine during the study; 13. local or systemic disease caused by non-malignancy, or disease or symptom secondary to tumor, that can lead to higher medical risk and/or uncertainty in survival;